PDF(Pubmed)
Abstract：
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a highly aggressive subtype associated with poor prognosis. The advent of HER2-targeted drugs, including monoclonal antibodies, tyrosine-kinase inhibitors (TKIs) and antibody-drug conjugates, has yielded improved prognosis for patients. Compared with widely used monoclonal antibodies, small-molecule TKIs have unique advantages including oral administration and favorable penetration of blood-brain barrier for brain metastatic BC, and reduced cardiotoxicity. Pyrotinib is an irreversible TKI of the pan-ErbB receptor, and has recently been shown to be clinically effective for the treatment of HER2-positive BC in metastatic and neoadjuvant settings. This review highlights the development on the application of pyrotinib-based therapeutic approaches in the clinical settings of HER2-positive BC.
摘要：
人表皮生长因子受体2（HER2）阳性乳腺癌（BC）是一种高度侵袭性的亚型，预后不良。HER2靶向药物的出现，包括单克隆抗体,酪氨酸激酶抑制剂（TKIs）和抗体-药物偶联物，改善了患者的预后。与广泛使用的单克隆抗体相比，小分子TKIs具有独特的优势，包括口服给药和对脑转移性BC的血脑屏障的良好渗透，减少心脏毒性.Pyrotinib是pan-ErbB受体的不可逆TKI，并且最近已证明在转移性和新辅助治疗中对HER2阳性BC的临床有效.这篇综述强调了基于吡罗替尼的治疗方法在HER2阳性BC临床环境中的应用进展。
